Trial Profile
A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Apr 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Selinexor (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Adverse reactions
- 22 Apr 2021 Status changed from active, no longer recruiting to completed.
- 18 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2020 Results published in the Gynecologic Oncology